Stub Period Comparative Data (Unaudited)

12 Months Ended

Dec. 31, 2017

Stub Period Comparative Data (Unaudited)

Stub Period Comparative Data

M. Stub Period Comparative Data (Unaudited)

The unaudited, condensed consolidated statements of earnings for the year ended December 31, 2016 and the six months ended December 31, 2015 is as follows:

	Year Ended		Six Months Ended
	December 31,		December 31,
	2016		2015
Revenues:
License and milestone fees	$	15,305	$	16,762
Royalty revenue		—		195
Non-cash royalty revenue related to the sale of future royalties		26,218		11,975
Research and development support		5,175		1,620
Clinical materials revenue		1,930		2,328
Total revenues		48,628		32,880
Operating Expenses:
Research and development		141,312		73,331
General and administrative		38,528		16,383
Restructuring charge		4,431		—
Total operating expenses		184,271		89,714
Loss from operations		(135,643)		(56,834)
Investment income, net		473		111
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes		(18,593)		(10,202)
Interest expense on convertible senior notes		(2,387)		—
Other expense, net		(583)		(42)
Net loss	$	(156,733)	$	(66,967)
Basic and diluted net loss per common share	$	(1.80)	$	(0.77)